Nathalie Javidi-Sharifi, MD, PhD

Nathalie Javidi-Sharifi, MD, PhD

Medical Oncology

Top Doctor Award Badge

Contact Information

Office Phone Number

617-632-6844

Fax

617-632-4422

Appointments

877-442-3324

Biography

Nathalie Javidi-Sharifi, MD, PhD

Dr. Javidi-Sharifi received her undergraduate degree in Biochemistry from the Technical University of Munich in Germany and her MD/PhD in Cancer Biology from Oregon Health & Science University. She completed residency training in Internal Medicine at Oregon Health & Science University and fellowship training in Hematology/Oncology at Dana-Farber Cancer Institute/Mass General Brigham. Upon completing fellowship, she joined the faculty at Dana-Farber Cancer Institute. She is an attending physician in the Lymphoma Division and an Instructor in Medicine at Harvard Medical School. Her clinical and research interests focus on chronic lymphocytic leukemia, small lymphocytic lymphoma, Richter transformation, and related lymphoid malignancies.

Researcher

Physician

Physician

Clinical Interests

Chronic lymphocytic leukemia, Lymphoma

Research

     

    Understanding progression and treatment resistance in chronic lymphocytic leukemia Dr. Javidi-Sharifi’s research focuses on understanding why some patients with chronic lymphocytic leukemia develop more aggressive disease, including Richter transformation. Her work combines clinical investigation with laboratory-based studies of patient samples to identify biologic features that may predict disease behavior and reveal new therapeutic vulnerabilities. The long-term goal of her research is to improve risk stratification and develop more personalized treatment approaches for patients with CLL and related lymphoid malignancies.

     

    Publications

      • MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms. Semin Hematol. 2025 Oct; 62(5):418-430. View in: Pubmed

      • Advances in the Management of Relapsed/Refractory CLL and Richter Transformation. Hematol Oncol. 2025 Jun; 43 Suppl 2:e70064. View in: Pubmed

      • The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. Blood Neoplasia. 2025 Aug; 2(3):100108. View in: Pubmed

      • A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies. Blood Adv. 2025 Feb 25; 9(4):820-832. View in: Pubmed

      • Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. Expert Rev Hematol. 2024 06; 17(6):201-210. View in: Pubmed

      • PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023 08 18; 22(1):138. View in: Pubmed

      • Future Directions in Chronic Phase CML Treatment. Curr Hematol Malig Rep. 2021 12; 16(6):500-508. View in: Pubmed

      • Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. Elife. 2019 Mar 29; 8. View in: Pubmed

      • FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 2019 02 05; 8. View in: Pubmed

      • LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene. 2019 02; 38(8):1200-1210. View in: Pubmed

      • FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Res. 2016 11 15; 76(22):6471-6482. View in: Pubmed

      • Mutations in G protein ß subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015 Jan; 21(1):71-5. View in: Pubmed

      • Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Res. 2015 Mar 01; 75(5):880-91. View in: Pubmed

      • Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood. 2014 Mar 06; 123(10):1516-24. View in: Pubmed

      Locations

      Brigham and Women's Hospital building

      Brigham and Women's Hospital

      75 Francis Street Boston, MA 02115
      Get Directions
      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Brigham and Women's Hospital

      Brigham and Women's Hospital building

      Brigham and Women's Hospital

      75 Francis Street Boston, MA 02115
      Get Direction
      42.3361, -71.1072

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1083

      Ratings and Comments

      Nathalie Javidi-Sharifi, MD, PhD

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights